Skip to main content

Day: February 26, 2025

LBMC Unveils Key Healthcare Trends for 2025: AI, M&A, Cybersecurity, and Policy Shifts Poised to Reshape the Industry

AI, Innovation, and the Future of Healthcare in 2025As AI adoption accelerates, healthcare organizations must navigate emerging technologies while ensuring data security and compliance.Nashville, Tenn., Feb. 26, 2025 (GLOBE NEWSWIRE) — As the healthcare landscape continues to evolve, industry leaders are facing a convergence of rapid innovation, regulatory shifts, and heightened cybersecurity concerns. Matt Cybulsky, LBMC Healthcare AI and Product Innovation expert, highlights key trends shaping 2025, including AI’s expanding role in diagnostics, an anticipated surge in mergers and acquisitions, and the increasing pressure on healthcare organizations to integrate technology while safeguarding sensitive data.    Key Healthcare Trends for 2025 AI’s Growing Contribution to Personalized Care and Diagnostics AI-driven...

Continue reading

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.”  The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025. The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in November 2022. “Strategic IP and patent expansion...

Continue reading

Dovre’s subsidiary Suvic Oy Receives Notice to Proceed and Begins Construction of a 100 MWp Solar Park in Eurajoki

Dovre Group Plc                Inside information                February 26, 2025, at 9 pm Dovre’s subsidiary Suvic Oy Receives Notice to Proceed and Begins Construction of a 100 MWp Solar Park in Eurajoki Suvic, a subsidiary of Dovre, has received a Notice to Proceed (NTP) and will commence work on the construction of a 100 MWp solar park in Luvia, Eurajoki, in accordance with the EPC contract announced earlier on January 8, 2025, at 5.15 pm. The client for the project is Alight, a Swedish solar power developer and independent energy producer. Additionally, the parties have signed an operation and maintenance (O&M) agreement for two years, with an option to extend for an additional three years. The solar park will cover a total area of 123 hectares and will be built in two locations: the Mikola site, spanning 73 hectares, and the...

Continue reading

Millicom (Tigo) declares $0.75 per share interim dividend to be paid on April 15, 2025

Millicom (Tigo) declares $0.75 per share interim dividend to be paid on April 15, 2025 Luxembourg, February 26, 2025 – In line with the press release published on January 14, 2025, the Board of Directors of Millicom International Cellular S.A. (“Millicom”) approved the interim dividend of $0.75 per share to be paid on April 15, 2025 (the “Payment Date”). Other important dates and information relating to the Interim Dividend are as follows:Interim Dividend Record Date: the Interim Dividend will be paid to shareholders who are registered in the U.S. with Broadridge on April 8, 2025, at 23.59 CET; Ex-dividend Date: the last trading day on which shares acquired will be eligible to receive the Interim Dividend payment, would be April 8, 2025; Currency: the Interim Dividends will be paid in U.S. dollars; Payment Date: holders of Millcom shares...

Continue reading

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) — Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro’s data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas. At the core of this collaboration is BioSymetrics’ proprietary Elion platform, a cutting-edge...

Continue reading

Good profitability and cash flow generation despite slower growth in 2024

Good profitability and cash flow generationdespite slower growth in 2024 2024 key figuresRevenue: €2,441 million (+2.1% compared to 2023)organic growth: +1.3% external growth: +2.3%Operating margin rate: 13.1% Free cash flow generation: €216 millionBen Page, CEO of Ipsos, stated: “Despite slowing growth, the improvement in gross margin and careful cost management enabled us to deliver a good level of profitability. Ipsos’ financial health is also reflected in strong cash generation, virtually debt-free status and Investment Grade ratings by Moody’s and Fitch. Our recent acquisitions have cemented our leadership in Public Affairs and Data Analytics. Finally, we will continue to invest in our panels, platforms and Generative AI to deliver even faster cutting-edge insights to our clients.” Paris, 26 February 2025 – Ipsos, one of...

Continue reading

Rezolve Ai’s Crypto Leadership Confirmed as PayPal Follows Suit with Stablecoin Strategy

Rezolve Ai’s Early Adoption of Stablecoin Payments Validated as PayPal Enters the Space with PYUSD NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) — PayPal Holdings Inc.’s recent launch of its PYUSD stablecoin initiative shows that the strategy Rezolve Ai (NASDAQ: RZLV) has been pioneering in cooperation with Tether – one of the largest companies in the digital asset industry – is gaining traction throughout the market. As PayPal moves into crypto payments, Rezolve Ai’s believes its foresight in enabling stablecoin transactions for everyday commerce is further validated, reinforcing its position as the leader in blockchain-powered retail solutions. Rezolve Ai’s braincheckout solution, being developed in collaboration with Tether, is designed to make crypto transactions as seamless as traditional payments. By integrating a non-custodial...

Continue reading

WENDEL: 2024 Full-Year Results: a very active year, a dual model in place, strong value creation & a growing return to shareholders

       2024 Full-Year Results: a very active year, a dual model in place, strong value creation & a growing return to shareholders Fully diluted1 Net Asset Value per share of €185.7, representing a +16.9% year-over-year value creation, adjusted for the dividend paid Dividend boosted at €4.7 per share, up +17.5% year-over-year Strong portfolio rotation: more than €2 billion of capital reallocation Significant expansion of the Asset Management platform in Europe and US, and development of our dual business model towards more recurring cash flows and growth Fully diluted Net Asset Value2 as of December 31, 2024: €185.7 per share, up +14.4%Value creation of +16.9%3 over 2024, adjusted for the €4 dividend paid in May 2024 reflecting:The increase in Bureau Veritas’ share price (+28.3% YoY) on the back of the quality of its LEAP |...

Continue reading

McPhy Energy: Monthly information relating to the total number of voting rights and outstanding shares (January 31, 2025)

In accordance with articles L. 233-8-II of the French Commercial Code and 223-16 of the Autorité des Marchés Financiers General Regulation Reporting company:Corporate name: McPhy Energy Public Limited company (société anonyme) with Board of Directors Registered office: Aéroparc – 1615 Avenue de la Grande Piste, 90150 Foussemagne Registered under number 502 205 917 R.C.S. Belfort Euronext Growth Paris (ISIN code: FR0011742329 – ALMCP)Date Total number of outstanding shares Total number of voting rights*Gross Net31/01/2025 29,281,788 29,281,788 29,155,275* Total number of voting rights (i) “gross” calculated on the basis of all the shares to which voting rights are attached, including those deprived of voting rights, (ii) “net” calculated on the basis of all the shares to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.